-
Express gene editing to create "ready-to-use" CAR-T therapy, phase 1 clinical trial results are positive
Time of Update: 2021-10-21
▎The content team editor of WuXi AppTec today, CRISPR Therapeutics announced that the allogeneic CAR-T cell therapy CTX110, modified with CRISPR gene editing technology, has achieved positive safety and efficacy in a phase 1 clinical trial for the treatment of CD19-positive B-cell cancers Result .
-
GU Highlight Prof. Wei Yu: A collection of advances in ESMO treatment of renal cell carcinoma in 2021
Time of Update: 2021-10-21
Renal cell carcinoma (RCC) is one of the common malignant tumors in the urinary system, and its incidence is increasing year by year . Due to the insidious early symptoms, about one-quarter to one-t
-
Professor Wang Liang: The treatment of Hodgkin's lymphoma is promising in the future!
Time of Update: 2021-10-21
Combined with HL patients, the baseline TMTV was divided into high and low groups by cut-off value (350ml), and the 2-year progression-free survival (PFS) rates were 93% and 81%, respectively .
-
Breast cancer bone metastases: Disulumab has superior efficacy, and early use will bring more benefits to patients!
Time of Update: 2021-10-21
Li Li’s case sharing The basic situation of the case: a female patient, 66 years old, went to see the doctor on April 7, 2021 for “6 years after right breast cancer surgery, left lower extremity pain for more than 6 months, worsening for 1 day” .
-
Cancer Cell Liu Zhihua/Zhang Zemin/Ma Fei/Xu Binghe collaborated to reveal the mechanism of action of Anti-PD-L1 immunotherapy combined with chemotherapy in triple-negative breast cancer
Time of Update: 2021-10-21
The research system compared the tumor microenvironment and peripheral blood immune characteristics of responding patients and non-responding patients, clarified the dynamic changes of immune cells under different treatment plans, and revealed the effect of anti-PD-L1 immunotherapy combined with paclitaxel chemotherapy in TNBC Mechanism of action .
-
Yiming Biotech announced that the new inhibitory antibody IO-108 targeting LILRB2 (ILT4) has completed the first case of drug delivery to patients with advanced solid tumors in the United States.
Time of Update: 2021-10-21
Recent popular reports from Yimaike ★Case sharing of cell therapy process innovation-Challenges in cell therapy production and the application of countercurrent centrifugation technology in closed production Yimai Meng broke the news ★ Conference invitation | Sartorius co-organized the first WuXi Gene Therapeutic Technology Forum October 15, 2021/MedClub News/--Palo Alto, USA, Hangzhou, China, in the clinical stage, dedicated to the development of targeted immunosuppressive myeloid immune checkpoints and innovative cancer immunotherapy organisms The pharmaceutical company Immune-Onc Therapeutics, Inc.
-
A unique label for the type of lung cancer that has never been smoked
Time of Update: 2021-10-21
This article is from NEJM Journal Watch Distinct Signatures of Lung Cancer Types in Never-Smokers.
The most aggressive tumors are the "forte" subtype; these tumors are dominated by whole-genome doubling mutations, have short telomeres and have aggressive behavior, and are most similar to smokers' lung cancer .
-
Professor Zhang Yu: Main points and progress of pathological diagnosis of solid tumors in children
Time of Update: 2021-10-21
At the meeting, Professor Zhang Yu from the Cancer Center of Sun Yat-sen University shared the key points of pathological diagnosis of solid tumors in children, and vividly introduced the importance of immunohistochemistry and molecular detection in pathological diagnosis and identification through cases .
-
MyPathway study proves that HER2 is a viable target for cholangiocarcinoma
Time of Update: 2021-10-21
Comment This trial shows that in HER2-positive cholangiocarcinoma patients, HER2 is a viable target for the development of new drugs .
-
Cyclophosphamide capsules are planned to be included in the priority review; this LAG-3 monoclonal antibody completes the first subject administration of tumor information
Time of Update: 2021-10-21
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
Case sharing Early use, more benefits!
Time of Update: 2021-10-21
2ng/ml, whole body bone scan revealed multiple bone metastases throughout the body (more than or equal to 2 new lesions), and there was bone related bone pain such as paraplegia In the event, consider the patient's progression from the mHSPC stage to the mCRPC stage; switch to the original abiraterone acetate + prednisone + ADT regimen .
-
[Prevention of cancer metastasis] Genetic testing may predict cancer metastasis organs in advance!
Time of Update: 2021-10-21
What is the main cause of death in patients with malignant tumors? A. Followed by blood B. C. Secondary infection Extensive transfer D. Pain For a long time, cancer has been artificially dressed
-
Effectively activate the body's immunity, new oncolytic immunotherapy helps the treatment of advanced pancreatic cancer
Time of Update: 2021-10-21
What will a new type of oncolytic virus bring to the treatment of patients with advanced pancreatic cancer?
Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma.
-
Express FDA today approved Keytruda combination therapy for first-line treatment of cervical cancer, reducing the risk of death by 36%
Time of Update: 2021-10-21
Retrieved October 13, 2021, from https:// approves-pembrolizumab-combination-first-line-treatment-cervical-cancer[2] FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD -L1 (CPS ≥1).
-
For the treatment of malignant pleural mesothelioma, dual immunotherapy is approved!
Time of Update: 2021-10-21
In June 2021, nivolumab injection (trade name: Odivo®) combined with ipilimumab injection (trade name: Yiwo®) was approved by the National Drug Administration of China Approved by NMPA for use in adult patients with non-epithelioid malignant pleural mesothelioma who are not resectable and newly treated .
-
Express CDK4/6 inhibitors received FDA approval for the first time to treat early-stage breast cancer
Time of Update: 2021-10-21
▎The content team editor of WuXi AppTec today, Eli Lilly and Company announced that the US FDA has approved the expanded indications of the CDK4/6 inhibitor Verzenio (abemaciclib), combined with endocrine therapy (tamoxifen or aromatase inhibition).
-
Climbing to the top of JCO again, KEYNOTE-024 sets a benchmark for domestic PD-1 inhibitors
Time of Update: 2021-10-21
For PD-L1 highly expressed driver gene-negative advanced non-small cell lung cancer (NSCLC), pembrolizumab The median overall survival (OS) of the first-line treatment of drugs and chemotherapy was 26.
-
Vaccination to shrink tumors, MIT scientists’ new discoveries are a step forward in the realization of cancer vaccines
Time of Update: 2021-10-21
They found that adding specific proteins to cancer vaccines can help release more T cell power, enhance the overall immune response, and achieve better anti-cancer effects .
-
Professor Huang He: New Progress in Research on Universal CAR-T Cells The 16th National Leukemia and Lymphoma Academic Conference
Time of Update: 2021-10-21
The research results reported at the 2018 ASH Conference showed that the CR/Complete Remission (CRi) rate with incomplete recovery of hematology reached 82% for the universal CAR-T treatment of B-cell acute lymphoblastic leukemia (B-ALL).
-
Molecular Cancer Fan Zusen/Tian Yong and others discover new potential therapeutic targets for hepatocellular carcinoma
Time of Update: 2021-10-21
40) entitled "Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling "In the research paper, this study identified highly conserved circRNAs in humans and mice from three primary HCC samples through the circRNA array .
